For instance, Dasatinib (BMS-354825), a small molecular inhibitor of multiple tyrosine kinases with an IC50 of 0.55 nM toward SRC and the similar IC50 for other tyrosine kinases of the SRC family, has been shown to inhibit the progression of chronic myelogenous leukemia (CML) and other cancer types (Sen and Johnson, 2011; Levitzki, 2013). Here, SRC is linked to cancer.